Loading...
01/11 03:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates positive sentiment due to operational efficiencies, strong AUSTEDO growth, and effective cost management. Despite revenue decline, gross and operating margins improved. Management's confidence in achieving targets, especially for AUSTEDO, and strategic focus on biosimilars and innovative pipeline add to positive sentiment. Q&A insights support growth and strategic alignment with market dynamics. Positive guidance on cost savings and debt reduction further enhances the outlook. Given these factors, the stock is likely to experience a positive impact, despite some uncertainties around Medicare pricing and CMS agreements.
Revenue $4.5 billion, up 3% year-over-year. Growth driven by innovative products and generics in the U.S., partially offset by softness in European generics and lower proceeds from product rights sales.
Adjusted EBITDA Up 6% year-over-year. Growth attributed to strong performance in innovative products and operational efficiencies.
Non-GAAP EPS $0.78, up 14% year-over-year. Increase driven by higher gross margin and operational improvements.
Free Cash Flow $515 million, down from $922 million in Q3 2024. Decrease due to timing of sales and collections, and higher legal settlement payments.
Net Debt to EBITDA Below 3x for the first time since 2016. Improvement due to consistent debt reduction and EBITDA growth.
Innovative Products Revenue Over $800 million for the quarter, up 33% year-over-year. Growth led by AUSTEDO (up 38% to $618 million), UZEDY (up 24% to $43 million), and AJOVY (up 19% to $168 million).
Global Generics Revenue Up 2% year-over-year. Growth driven by U.S. launches and biosimilars, partially offset by declines in Europe.
TAPI Revenue Down 4% year-over-year. Decline attributed to seasonal volatility.
Non-GAAP Gross Margin 55.3%, up 120 basis points year-over-year. Increase driven by strong growth in AUSTEDO and favorable portfolio mix.
Non-GAAP Operating Margin 28.9%, up 70 basis points year-over-year. Improvement due to higher gross margin and operational efficiencies.
AUSTEDO: Achieved $618 million in Q3 2025, growing 38% year-over-year. Revenue outlook for 2025 increased to $2.05 billion to $2.15 billion. Peak sales target of over $3 billion remains intact.
UZEDY: Revenue grew 24% year-over-year to $43 million. Expanded indication for bipolar I disorder. Peak sales target of $1.5 billion to $2 billion.
AJOVY: Revenue grew 19% year-over-year to $168 million. Confirmed guidance of $630 million to $640 million for 2025.
Generics Business: Revenue grew 2% year-over-year, driven by U.S. launches and biosimilars. European generics declined 5% due to tough comparisons.
Biosimilars: 10 in-line assets globally with potential to launch 6 more by 2027. Expected to add $400 million by 2027.
Cost Savings Program: On track to achieve $700 million in savings by 2027, with 2/3 realized by 2026. Approximately half of the 2025 target already achieved.
Net Debt Reduction: Net debt-to-EBITDA reduced to below 3x for the first time since 2016. Targeting 2x by 2027.
Innovative Pipeline: Late-stage assets include olanzapine LAI, DARI, duvakitug, and emrusolmin. Potential peak sales of over $11 billion.
TAPI Divestment: Renewed sale process initiated after failing to reach agreement with initial buyer. TAPI remains non-strategic to growth priorities.
Market Conditions: Seasonal volatility in TAPI and softness in European generics markets, including tough comparisons to prior years and tender wins.
Regulatory Hurdles: AUSTEDO selected for CMS 2027 price negotiation, which could impact pricing dynamics. Additionally, potential U.S. tariffs on pharmaceuticals remain uncertain.
Supply Chain Disruptions: No explicit mention of supply chain disruptions, but seasonal volatility in TAPI could imply operational challenges.
Economic Uncertainties: Geopolitical shifts and market conditions affecting the attractiveness of TAPI for potential buyers.
Strategic Execution Risks: Challenges in divesting TAPI due to inability to reach an agreement with a buyer, impacting strategic focus and resource allocation. Additionally, reliance on achieving $700 million in cost savings by 2027 and executing late-stage innovative programs on time.
Competitive Pressures: AJOVY operates in a highly competitive market, and biosimilars face challenges in Europe, the largest biosimilar market.
Revenue Growth: Teva expects to achieve mid-single-digit revenue growth by 2027, with a 3% to 4% growth range estimated for 2025.
AUSTEDO Revenue Outlook: The company has increased its 2025 revenue outlook for AUSTEDO to $2.05 billion to $2.15 billion, with a 2027 revenue target of $2.5 billion and peak sales exceeding $3 billion.
UZEDY Revenue and Market Potential: Teva reiterates its peak sales target of $1.5 billion to $2 billion for UZEDY, supported by strong TRx growth and expanded indications. Q4 2025 revenue guidance for UZEDY is $55 million to $65 million.
AJOVY Revenue Guidance: Teva confirms its 2025 revenue guidance for AJOVY at $630 million to $640 million.
Innovative Pipeline and Future Growth: Teva anticipates over $11 billion in peak sales from its late-stage innovative pipeline, including olanzapine LAI, DARI, duvakitug, emrusolmin, and anti-IL-15 programs. Key milestones include FDA submission for olanzapine LAI in late 2025 and Phase III progress for other assets.
Generics and Biosimilars: Teva forecasts $400 million in additional biosimilar revenue by 2027, with significant contributions expected post-2027 from European launches.
Operating Margin and Cost Savings: Teva is on track to achieve a 30% operating margin by 2027, supported by $700 million in cost savings from its transformation program, with two-thirds of savings realized by 2026.
Net Debt-to-EBITDA: Teva expects to reduce its net debt-to-EBITDA ratio to 2x by 2027, with a 2025 year-end target of 2.8x.
Dividend Program: No specific mention of a dividend program was made during the call.
Share Buyback Program: The presentation did not discuss any share buyback program or shareholder return plan.
The earnings call indicates positive sentiment due to operational efficiencies, strong AUSTEDO growth, and effective cost management. Despite revenue decline, gross and operating margins improved. Management's confidence in achieving targets, especially for AUSTEDO, and strategic focus on biosimilars and innovative pipeline add to positive sentiment. Q&A insights support growth and strategic alignment with market dynamics. Positive guidance on cost savings and debt reduction further enhances the outlook. Given these factors, the stock is likely to experience a positive impact, despite some uncertainties around Medicare pricing and CMS agreements.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
